Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis

American Journal of Obstetrics and Gynecology

Volumn 203, Issue 6, 2010, Pages 584.e1-584.e22

  Shih, Ie Ming ^a   Chen, Li ^b   Wang, Chen C ^b   Gu, Jinghua ^b   Davidson, Ben ^c   Cope, Leslie ^a   Kurman, Robert J ^a   Xuan, Jianhua ^b   Wang, Tian Li ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b State University   (United States)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Methylation; Ovarian carcinoma

Indexed keywords

HISTONE DEACETYLASE 6; MITOGEN ACTIVATED PROTEIN KINASE 4; TRANSCRIPTION FACTOR HOXA9; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN; WNT5A PROTEIN;

ARTICLE; CANCER GRADING; CARCINOGENESIS; CARCINOMA; CLUSTER ANALYSIS; CONTROLLED STUDY; CYSTADENOMA; DNA METHYLATION; FEMALE; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MUTATIONAL ANALYSIS; OVARY CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; STROMA CELL; TUMOR CELL; TUMOR GROWTH; TUMOR RECURRENCE; ADULT; AGED; CANCER STAGING; CELL TRANSFORMATION; COMPARATIVE STUDY; CYSTADENOCARCINOMA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PROGNOSIS;

ADULT; AGED; CELL TRANSFORMATION, NEOPLASTIC; CYSTADENOCARCINOMA, SEROUS; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 79952116756     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2010.08.003     Document Type: Article

References (34)

1. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54. (Pubitemid 37448928)
2. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer: a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6: 107-16. (Pubitemid 43361543)
3. Satoh Y, Nakagawachi T, Nakadate H, et al. Significant reduction of WT1 gene expression, possibly due to epigenetic alteration in Wilms' tumor. J Biochem 2003;133:303-8. (Pubitemid 36504397)
4. Kaneuchi M, Sasaki M, Tanaka Y, et al. WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer 2005;104:1924-30. (Pubitemid 41513176)
5. Li Y, Hu W, Shen DY, Kavanagh JJ, Fu S. Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. Am J Obstet Gynecol 2009;200:177.e1-9.
6. Wei SH, Chen CM, Strathdee G, et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 2002;8: 2246-52. (Pubitemid 34753597)
7. Wiley A, Katsaros D, Chen H, et al. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 2006; 107:299-308. (Pubitemid 44036559)
8. Sellar GC, Watt KP, Rabiasz GJ, et al. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet 2003;34:337-43. (Pubitemid 36792869)
9. Choi Yl, Kang SY, Shin YK, et al. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas. Virchows Arch 2006;448:331-6. (Pubitemid 43357650)
10. Ibanez De Caceres I, Battagli C, Esteller M, et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 2004;64:6476-81. (Pubitemid 39297903)
11. Houshdaran S, Hawley S, Palmer C, et al. DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines. PLoS One 2010;5:e9359.
12. Feng Q, Deftereos G, Hawes SE, et al. DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma. Gynecol Oncol 2008;111:320-9.
13. Fiegl H, Windbichler G, Mueller-Holzner E, et al. HOXA11 DNA methylation: a novel prognostic biomarker in ovarian cancer. Int J Cancer 2008;123:725-9. (Pubitemid 351898435)
14. Chou JL, Su HY, Chen LY, et al. Promoter hypermethylation of FBXO32, a novel TGFbeta/ SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab Invest 2010;90:414-25.
15. Hoque MO, Begum S, Brait M, et al. Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer. J Urol 2008;179:743-7.
16. Mandelker DL, Yamashita K, Tokumaru Y, et al. PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res 2005; 65:4963-8. (Pubitemid 40740837)
17. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009;27:5874-80.
18. Ye Y, McDevitt MA, Guo M, et al. Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. Cancer Res 2009;69: 8482-90.
19. Barton CA, Hacker NF, Clark SJ, O'Brien PM. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol 2008;109: 129-39.
20. Shih I-M, Kurman RJ. Ovarian tumorigenesis-a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164:1511-8. (Pubitemid 38529752)
21. Shih IE M, Wang Tl. Apply innovative technologies to explore cancer genome. Curr Opin Oncol 2005;17:33-8.
22. Seo J, Shneiderman B. Interactively exploring hierarchical clustering results. IEEE Computer 2002;35:80-6.
23. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21. (Pubitemid 32397092)
24. Cho KR, Shih IM. Ovarian cancer. Annu Rev Pathol Mech Dis 2009;4:287-313.
25. Shih IeM, Kurman RJ. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 2005; 11:7273-9. (Pubitemid 41507684)
26. Kurman RJ, Shih IeM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008;27:151-60. (Pubitemid 351450677)
27. Singer G, Kurman RJ, Chang H-W, Cho SKR, Shih I-M. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002; 160:1223-8. (Pubitemid 34411626)
28. Singer G, Oldt R 3rd, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003;95:484-6. (Pubitemid 36432423)
29. Kuo K, Mao T, Feng Y, et al. DNA copy number profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res 2010;16: 1997-2008.
30. Kuo KT, Guan B, Feng Y, et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res 2009;69:4036-42.
31. Ho C-L, Kurman RJ, Dehari R, Wang T-L, Shih I-M. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 2004;64:6915-8. (Pubitemid 39330999)
32. Dehari R, Kurman RJ, Logani S, Shih IM. The Development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Am J Surg Pathol 2007;31: 1007-12. (Pubitemid 47012296)
33. Wang F, Zhu Y, Huang Y, et al. Transcriptional repression of WEE1 by Kruppel-like factor 2 is involved in DNA damage-induced apoptosis. Oncogene 2005;24:3875-85. (Pubitemid 40896399)
34. Yoshida T, Tanaka S, Mogi A, Shitara Y, Kuwano H. The clinical significance of cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol 2004;15:252-6. (Pubitemid 38262624)